Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16848313 | 0.90 | CYP4F2 (0.47) | CYP4F2CYP4A11EPHX2ALDH1A1GAA | |
| SCHEMBL15936212 | 0.86 | CYP4F2 (0.48) | CYP4F2CYP4A11EPHX2ALDH1A1GAA | |
| SCHEMBL5113092 | 0.85 | CYP4F2 (0.47) | CYP4F2CYP4A11EPHX2ALDH1A1GAA | |
| SCHEMBL28851037 | 0.83 | CYP4F2 (0.45) | CYP4F2CYP4A11EPHX2ALDH1A1GAA | |
| SCHEMBL435614 | 0.81 | CHRNA7 (0.55) | CYP4F2CYP4A11ALDH1A1GAAKDM4E | |
| SCHEMBL4081569 | 0.81 | EPHX2 (0.65) | CYP4F2CYP4A11EPHX2ALDH1A1GAA | |
| SCHEMBL1549287 | 0.81 | CYP4F2 (0.54) | CYP4F2CYP4A11ALDH1A1GAAKDM4E | |
| SCHEMBL4521152 | 0.81 | CYP4F2 (0.58) | CYP4F2CYP4A11ALDH1A1GAAKDM4E | |
| SCHEMBL434221 | 0.81 | CYP4F2 (0.58) | CYP4F2CYP4A11CA12CA1CA2 | |
| SCHEMBL23655319 | 0.80 | IAPP (0.47) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254647-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-22 | — | — | US | disclosed |
| US-11230526-B1 | Cylcoalkenyl derivatives useful as agonists of the GPR120 and/or GPR40 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-25 | — | — | US | disclosed |
| EP-3409671-B1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-21 | — | — | EP | disclosed |
| EP-3409671-B1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-21 | — | — | EP | disclosed |
| US-20210024483-A1 | HETEROCYLCOALKENYL DERIVATIVES USEFUL AS AGONISTS OF THE GPR120 AND / OR GPR40 | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-28 | — | — | US | disclosed |
| EP-3421458-B1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-11 | — | — | EP | disclosed |
| US-20200317629-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-08 | — | — | US | disclosed |
| US-10730847-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-04 | — | — | US | disclosed |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICALS NV (BE) | 2020-04-14 | — | — | US | disclosed |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICALS NV (BE) | 2020-04-14 | — | — | US | disclosed |
| WO-2014159054-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014159054-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014159061-A2 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275172-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275179-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275179-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275179-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-20060257987-A1 | Ppar modulators | ELI LILLY AND COMPANY | 2006-11-16 | — | — | US | disclosed |
| EP-1660428-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024483-A1 | HETEROCYLCOALKENYL DERIVATIVES USEFUL AS AGONISTS OF THE GPR120 AND / OR GPR40 | GPR119, GPR65, GPR55 | CYP4F2 1196/4885CYP4A11 652/4885EPHX2 1123/4885 |
| US-20200317629-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | CYP4F2 1133/4885CYP4A11 1112/4885EPHX2 1256/4885 |
| US-20140275172-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | CYP4F2 1133/4885CYP4A11 1112/4885EPHX2 1256/4885 |
| US-11230526-B1 | Cylcoalkenyl derivatives useful as agonists of the GPR120 and/or GPR40 receptors | GPR119, GPR65, GPR55 | CYP4F2 2530/4885CYP4A11 1061/4885EPHX2 1419/4885 |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | GPR119, GLP1R, GCGR | CYP4F2 2590/4885CYP4A11 631/4885EPHX2 3130/4885 |
| US-11254647-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | CYP4F2 1133/4885CYP4A11 1112/4885EPHX2 1256/4885 |
| US-10730847-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | CYP4F2 1133/4885CYP4A11 1112/4885EPHX2 1256/4885 |
| US-20140275179-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GLP1R, GCGR | CYP4F2 2590/4885CYP4A11 631/4885EPHX2 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.